Christer Nordstedt

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

Part of Teva Pharmaceutical Industries Ltd., Teva GmbH is a German company that aims to provide high-quality medications to improve the quality of life for patients. The company is based in Ulm, Germany. The CEOs are Andreas Burkhardt, Thomas Andreas Schlenker. The company was founded in 2011 by Chaim Salomon, Günther Friedländer, Moshe Levinson, Yitschak Elstein.